YOLFTbeta
NetraMark Holdings Inc.

NetraMark Holdings Inc.

AIAI · TO · Healthcare / Health Information Services

0.60CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.60
Open0.62
Day Range0.55 – 0.62
52-Week Range0.59 – 1.12
Volume52.23K
Market Cap63.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.07
Dividend Yield0.00%
Beta1.49
50-Day Avg0.70
200-Day Avg0.8822

About

NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. George Achilleos
  • Headquarters1655 Dupont Street, Toronto, ON, Canada, M6P 3T1, Canada
  • Websitehttps://www.netramark.com

Leadership

  • Mr. George AchilleosPresident, CEO & Director
  • Dr. Joseph Geraci Ph.D.Founder, Chief Scientific & Technical Officer and Director
  • Mr. Swapan Kakumanu ACA, ACWA, CGACFO & Corporate Secretary · b. 1970
  • Mr. Josh SpiegelPresident of NetraMark Corp
  • Ms. Jaime HackettVice President of Marketing
  • Dr. Luca Pani M.D.Chief Innovation & Regulatory Officer and Chief Medical Advisor
  • Dr. Kaveh KavoosiHead of Progressive Medicine
  • Dr. Angelico Carta M.D.Chief Strategy Officer
  • Dr. Jan Sedway Ph.D.Senior Vice President of Clinical Science
  • Dr. Panteli Theocharous M.S., Ph.D.Fractional Chief Medical Officer

Financials

Income Statement

Currency: CAD2022-09-302023-09-302024-09-302025-09-30
Total Revenue113.03K89.27K456.13K432.50K
Growth (%)--21.02%+410.96%-5.18%
Operating Income-7.93M-14.17M-3.33M-5.26M
Operating Margin-7017.57%-15872.15%-730.45%-1216.92%
EBITDA-7.34M-5.25M-3.33M-5.22M
EBITDA Margin-6489.48%-5879.00%-730.45%-1207.27%
Net Income-13.45M-14.17M-3.33M-5.22M
Net Income Margin-11897.34%-15872.15%-730.45%-1207.27%

Balance Sheet

Currency: CAD2022-09-302023-09-302024-09-302025-09-30
Total Assets9.20M1.91M207.57K2.18M
Total Liabilities1.09M824.41K406.13K342.17K
Total Equity8.11M1.09M-198.56K1.83M
Cash10.09K1.78M59.75K1.50M

Cash Flow

Currency: CAD2022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-4.78M-2.39M-2.29M-3.81M
Investing Cash Flow-0-150-513.75K
Financing Cash Flow691.58K4.16M573.00K5.76M
Capital Expenditure152.49K000
Free Cash Flow-4.93M-2.39M-2.29M-3.81M
FCF to OCF103.19%100.00%100.00%100.00%

Earnings

Report DateMar 31, 2026Jun 30, 2026
EPS Estimate--
EPS Actual-0.02-0.02
Surprise--
Timing--

Key Statistics & Ratios

Market Cap63.40M
Enterprise Value58.34M
Trailing P/E0.00
Forward P/E0.00
Price / Sales104.63
Price / Book20.61
EPS-0.07
Book Value0.032
Revenue (TTM)605.97K
Gross Profit (TTM)605.97K
Profit Margin0.00%
Operating Margin-336.93%
Return on Equity-314.71%
Return on Assets-158.74%
Shares Outstanding94.63M
Shares Float80.42M
Beta1.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%